<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04629404</url>
  </required_header>
  <id_info>
    <org_study_id>LY03003/CT-CHN-105</org_study_id>
    <nct_id>NCT04629404</nct_id>
  </id_info>
  <brief_title>A Clinical Trial to Evaluate the Pharmacodynamics/Pharmacokinetics and Safety of LY03003 in Early PD Patients</brief_title>
  <official_title>A Randomized, Double-Blind, Placebo-Controlled Clinical Trial to Evaluate the Pharmacodynamics/Pharmacokinetics and Safety of Multiple Intramuscular Doses of LY03003 in Patients With Early Parkinson's Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Luye Pharma Group Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Luye Pharma Group Ltd.</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A Clinical Trial to Evaluate the Pharmacodynamics/Pharmacokinetics and Safety of LY03003 in&#xD;
      Early PD Patients&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">November 5, 2018</start_date>
  <completion_date type="Actual">March 14, 2019</completion_date>
  <primary_completion_date type="Actual">March 14, 2019</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pharmacodynamic Measures</measure>
    <time_frame>From titration to dose-maintenance at day 50</time_frame>
    <description>Change from baseline in (II + III) total score, Part II, Part III scores of the UPDRS</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety Measures</measure>
    <time_frame>From titration to dose-maintenance at day 50</time_frame>
    <description>Blood Pressure</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Cmax,ss</measure>
    <time_frame>From titration to dose-maintenance at day 50</time_frame>
    <description>Peak concentration</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">32</enrollment>
  <condition>Parkinson Disease</condition>
  <arm_group>
    <arm_group_label>LY03003</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LY03003</intervention_name>
    <description>Firstly, intramuscularly inject 14 mg of the study drug once, continue intramuscularly inject 28 mg of the study drug once after being observed for 1 week to confirm safety, continue intramuscularly inject 42 mg of the study drug once after being observed for 1 week to confirm safety, and prepare to enter the maintenance period of 56 mg dose after being observed for 1 week to confirm safety. During the dose maintenance period, 56 mg of the test drug was intramuscularly injected once a week for a total of 4 consecutive doses.</description>
    <arm_group_label>LY03003</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Firstly, intramuscularly inject 14 mg of the study drug once, continue intramuscularly inject 28 mg of the study drug once after being observed for 1 week to confirm safety, continue intramuscularly inject 42 mg of the study drug once after being observed for 1 week to confirm safety, and prepare to enter the maintenance period of 56 mg dose after being observed for 1 week to confirm safety. During the dose maintenance period, 56 mg of the test drug was intramuscularly injected once a week for a total of 4 consecutive doses.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. the subject or his legal representative understands and is willing to participate in&#xD;
             this clinical study and voluntarily signs and dates the informed consent form;&#xD;
&#xD;
          2. in the judgment of the investigator, the subject or his legal representative is&#xD;
             considered trustworthy and able to comply with the study protocol, visit plan or&#xD;
             receive the study drug as required;&#xD;
&#xD;
          3. Subjects aged ≥ 30 years at screening (Visit 1), male or female;&#xD;
&#xD;
          4. Meet the UK Brain Bank diagnostic criteria for essential Parkinson's disease, duration&#xD;
             of illness ≤ 5 years, the diagnosis is based on the main sign - bradykinesia, plus at&#xD;
             least one of the following symptoms: resting tremor, rigidity or postural reflex&#xD;
             disorders, and no other known or suspected cause of Parkinson's disease;&#xD;
&#xD;
          5. Hoehn-Yahr stage ≤ 3 (excluding stage 0) in the &quot;on&quot; state;&#xD;
&#xD;
          6. Mini-Mental State Examination (MMSE) ≥ 25 points;&#xD;
&#xD;
          7. At baseline (Visit 2), the Unified Parkinson's Disease Rating Scale (UPDRS) motor&#xD;
             score (Part III) in the &quot;on&quot; state is ≥ 10;&#xD;
&#xD;
          8. if the subject is receiving anticholinergic drugs (e.g., methenamine, diphenhydramine,&#xD;
             diethylpromethazine, procyclidine, and biperiden), monoamine oxidase B (MAO-B)&#xD;
             inhibitors (e.g., selegiline, rasagiline), N-methyl-d-aspartate (NMDA) antagonists&#xD;
             (e.g., amantadine), the dose must be stable for at least 28 days before baseline&#xD;
             (Visit 2), and the dose must be maintained during the study;&#xD;
&#xD;
          9. Women of childbearing age (do not meet any of the following conditions: cessation of&#xD;
             menstruation for ≥ 12 months; or underwent hysterectomy or oophorectomy; or have&#xD;
             medically confirmed ovarian failure) or male subjects agree to take reliable&#xD;
             contraception (oral contraceptives, use of condoms, abstinence, etc.) throughout the&#xD;
             study (screening visit to the end of the study), and screening (Visit 1) and baseline&#xD;
             (Visit 2), women of childbearing age pregnancy test results are negative.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. history of pallidotomy, thalamic lesioning, deep brain stimulation or fetal tissue&#xD;
             transplantation;&#xD;
&#xD;
          2. suffering from dementia, active mental illness or hallucinations, major depression;&#xD;
&#xD;
          3. Patients receiving dopamine agonist therapy within 28 days before baseline (Visit 2);&#xD;
&#xD;
          4. received levodopa preparations (containing levodopa compound preparations) within 28&#xD;
             days before baseline (Visit 2);&#xD;
&#xD;
          5. received any of the following drugs within 28 days before baseline (Visit 2):&#xD;
             amphetamine, metoclopramide, α-methyldopa, anti-schizophrenia drugs, monoamine oxidase&#xD;
             A (MAO-A) inhibitors, reserpine, methylphenidate, cloth;&#xD;
&#xD;
          6. Receiving central nervous system active drug treatment (such as sedative hypnotics,&#xD;
             antidepressants, anxiolytics), but excluding the baseline (Visit 2) has remained&#xD;
             stable for at least 28 days, and may remain stable during the study;&#xD;
&#xD;
          7. Atypical Parkinson's disease symptoms caused by taking drugs (such as metoclopramide,&#xD;
             flunarizine), nervous system inherited metabolic diseases (such as Wilson's disease),&#xD;
             encephalitis, cerebrovascular disease or degenerative diseases (such as progressive&#xD;
             supranuclear palsy);&#xD;
&#xD;
          8. History of epilepsy, or stroke or transient ischemic attack within 1 year before&#xD;
             screening (Visit 1);&#xD;
&#xD;
          9. intolerant or allergic to the following antiemetics, such as domperidone,&#xD;
             trimethobenzamide, ondansetron, tropisetron, granisetron and gronium;&#xD;
&#xD;
         10. Clinically significant liver dysfunction, defined as total bilirubin &gt; 1.5 times the&#xD;
             upper limit of the reference range or alanine aminotransferase (ALT) or aspartate&#xD;
             aminotransferase (AST) &gt; 2 times the upper limit of the reference range;&#xD;
&#xD;
         11. Clinically significant renal dysfunction (serum creatinine &gt; 2.0 mg/dL [&gt; 177&#xD;
             μmol/L]);&#xD;
&#xD;
         12. uncontrolled or significant cardiovascular disease, including New York Heart&#xD;
             Association (NYHA) class II or higher congestive heart failure, unstable angina,&#xD;
             myocardial infarction within 6 months before baseline (Visit 2), or arrhythmia&#xD;
             requiring treatment at screening (Visit 1);&#xD;
&#xD;
         13. At screening (Visit 1) and baseline (Visit 2), QTc interval: male &gt; 470 ms, female &gt;&#xD;
             480 ms;&#xD;
&#xD;
         14. History of symptomatic orthostatic hypotension; or a systolic blood pressure decrease&#xD;
             of ≥ 20 mmHg or a diastolic blood pressure decrease of ≥ 10 mmHg at 1 or 3 minutes&#xD;
             from a recumbent to an upright position at screening (Visit 1) and baseline (Visit 2);&#xD;
             or a supine systolic blood pressure &lt; 105 mmHg at screening (Visit 1) and baseline&#xD;
             (Visit 2);&#xD;
&#xD;
         15. History of suicide attempt (including actual attempts, interrupted attempts, or failed&#xD;
             attempts) or suicidal ideation in the past 6 months, defined as &quot;yes&quot; to question 4 or&#xD;
             5 on the Columbia-Suicide Severity Rating Scale (C-SSRS) at screening (Visit 1);&#xD;
&#xD;
         16. History of narcolepsy;&#xD;
&#xD;
         17. History of alcoholism, drug abuse, or drug abuse within 5 years before screening&#xD;
             (Visit 1), defined as alcohol consumption of more than 14 units of alcohol per week (1&#xD;
             unit = 360 ml of beer or 45 ml of spirits with an alcohol content of 40% or 150 ml of&#xD;
             wine);&#xD;
&#xD;
         18. Patients with malignant tumors within 5 years before screening (Visit 1), except for&#xD;
             adequately treated cervical carcinoma in situ, basal cell or squamous cell carcinoma&#xD;
             of the skin, local prostate cancer after radical surgery, and intraductal carcinoma in&#xD;
             situ after radical surgery;&#xD;
&#xD;
         19. Pregnant or lactating women;&#xD;
&#xD;
         20. Previous participation in the rotigotine test can not tolerate or poor efficacy;&#xD;
             Allergic constitution or known allergy to rotigotine or rotigotine microsphere&#xD;
             preparation components;&#xD;
&#xD;
         21. Allergic constitution or known allergy to rotigotine or rotigotine microsphere&#xD;
             preparation components;&#xD;
&#xD;
         22. Participated in other drug clinical trials within 3 months before screening (Visit 1);&#xD;
&#xD;
         23. have other clinically significant medical conditions, psychiatric conditions or&#xD;
             laboratory abnormalities that may interfere with the ability of the subject to&#xD;
             participate in this study as judged by the investigator.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Shengjing Hospital of China Medical University</name>
      <address>
        <city>Shenyang</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>November 2020</verification_date>
  <study_first_submitted>November 5, 2020</study_first_submitted>
  <study_first_submitted_qc>November 13, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">November 16, 2020</study_first_posted>
  <last_update_submitted>November 13, 2020</last_update_submitted>
  <last_update_submitted_qc>November 13, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">November 16, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>parkinson disease</keyword>
  <keyword>LY03003</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Parkinson Disease</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

